Home The Word Brain	My Amedeo FAQ Privacy About	Flying Publisher
	The Angels Initiative Stroke prevention

Breast Cancer

Free Subscription Articles published in J Clin Oncol Retrieve available abstracts of 178 articles: HTML format

Single Articles

August 2022
1. OFFERSEN BV, Alsner J, Nielsen HM, Jakobsen EH, et al
   Partial Breast Irradiation Versus Whole Breast Irradiation for Early Breast Cancer Patients in a Randomized Phase III Trial: The Danish Breast Cancer Group Partial Breast Irradiation Trial.
   J Clin Oncol. 2022 Aug 5:JCO2200451. doi: 10.1200/JCO.22.00451.
   PubMed     Abstract available
   
   
   
2. MOY B, Rumble RB, Carey LA
   Chemotherapy and Targeted Therapy for Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer That Is Either Endocrine-Pretreated or Hormone Receptor-Negative: ASCO Guideline Rapid Recommendation Update.
   J Clin Oncol. 2022 Aug 4:JCO2201533. doi: 10.1200/JCO.22.01533.
   PubMed     Abstract available
   
   
   July 2022
3. JOHANSSON A, Dar H, van 't Veer LJ, Tobin NP, et al
   Twenty-Year Benefit From Adjuvant Goserelin and Tamoxifen in Premenopausal Patients With Breast Cancer in a Controlled Randomized Clinical Trial.
   J Clin Oncol. 2022 Jul 21:JCO2102844. doi: 10.1200/JCO.21.02844.
   PubMed     Abstract available
   
   
   
4. RUGO HS, Umanzor GA, Barrios FJ, Vasallo RH, et al
   Open-Label, Randomized, Multicenter, Phase III Study Comparing Oral Paclitaxel Plus Encequidar Versus Intravenous Paclitaxel in Patients With Metastatic Breast Cancer.
   J Clin Oncol. 2022 Jul 20:JCO2102953. doi: 10.1200/JCO.21.02953.
   PubMed     Abstract available
   
   
   
5. ULAS KAHYA B, Sutcuoglu O, Yazici O, Ozdemir N, et al
   Early Local Therapy for the Primary Site in De Novo Stage IV Breast Cancer: Results of a Randomized Clinical Trial (EA2108).
   J Clin Oncol. 2022 Jul 12:JCO2200404. doi: 10.1200/JCO.22.00404.
   PubMed    
   
   
   
6. SORAN A, Aytac O, Ozbas S
   Locoregional Therapy for Intact Primary Tumor in De Novo Stage IV Breast Cancer.
   J Clin Oncol. 2022 Jul 12:JCO2200802. doi: 10.1200/JCO.22.00802.
   PubMed    
   
   
   
7. LU Y, Meng D, Hui B, Yuan W, et al
   The Deep Inspiration Breath-Hold Technique May Be a Win-Win Option for the Treatment of Patients in Node-Positive Early Left-Sided Breast Cancer.
   J Clin Oncol. 2022 Jul 5:JCO2200931. doi: 10.1200/JCO.22.00931.
   PubMed    
   
   
   June 2022
8. COBAIN EF, Hayes DF
   Recent Advances in Adjuvant Endocrine Therapy in Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer.
   J Clin Oncol. 2022 Jun 29:JCO2200702. doi: 10.1200/JCO.22.00702.
   PubMed    
   
   
   
9. HUOBER J, Barrios CH, Niikura N, Jarzab M, et al
   Atezolizumab With Neoadjuvant Anti-Human Epidermal Growth Factor Receptor 2 Therapy and Chemotherapy in Human Epidermal Growth Factor Receptor 2-Positive Early Breast Cancer: Primary Results of the Randomized Phase III IMpassion050 Trial.
   J Clin Oncol. 2022 Jun 28:JCO2102772. doi: 10.1200/JCO.21.02772.
   PubMed     Abstract available
   
   
   
10. HENRY NL, Somerfield MR, Dayao Z, Elias A, et al
    Biomarkers for Systemic Therapy in Metastatic Breast Cancer: ASCO Guideline Update.
    J Clin Oncol. 2022 Jun 27:JCO2201063. doi: 10.1200/JCO.22.01063.
    PubMed     Abstract available
    
    
    
11. CHEN YJ, Yeh MH, Wei JC
    Considerations of Subgroup Classification When Analyzing Risk of Developing Cardiometabolic Risk Factors in Patients With Breast Cancer.
    J Clin Oncol. 2022 Jun 16:JCO2200416. doi: 10.1200/JCO.22.00416.
    PubMed    
    
    
    
12. PHILLIPS KA, Friedlander ML
    Risk of Peritoneal Cancer After Risk-Reducing Bilateral Salpingo-Oophorectomy for Women With Germline BRCA Pathogenic Variants: A Cause for Concern or Potentially Avoidable?
    J Clin Oncol. 2022;40:1850-1852.
    PubMed    
    
    
    
13. STEENBEEK MP, van Bommel MHD, Bulten J, Hulsmann JA, et al
    Risk of Peritoneal Carcinomatosis After Risk-Reducing Salpingo-Oophorectomy: A Systematic Review and Individual Patient Data Meta-Analysis.
    J Clin Oncol. 2022;40:1879-1891.
    PubMed     Abstract available
    
    
    
14. REDING KW, Cheng RK, Barac A, Vasbinder A, et al
    Toward a Better Understanding of the Differential Impact of Heart Failure Phenotypes After Breast Cancer.
    J Clin Oncol. 2022 Jun 10:JCO2200111. doi: 10.1200/JCO.22.00111.
    PubMed    
    
    
    
15. MITTENDORF EA, King TA, Tolaney SM
    Impact of RxPONDER and monarchE on the Surgical Management of the Axilla in Patients With Breast Cancer.
    J Clin Oncol. 2022 Jun 8:JCO2200173. doi: 10.1200/JCO.22.00173.
    PubMed    
    
    
    
16. CESCON DW, Kalinsky K, DeMichele AM
    Can a Late Interception by Circulating Tumor DNA Deliver a Win in Estrogen Receptor-Positive Early Breast Cancer?
    J Clin Oncol. 2022 Jun 4:JCO2201026. doi: 10.1200/JCO.22.01026.
    PubMed    
    
    
    
17. LIPSYC-SHARF M, de Bruin EC, Santos K, McEwen R, et al
    Circulating Tumor DNA and Late Recurrence in High-Risk Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer.
    J Clin Oncol. 2022 Jun 4:JCO2200908. doi: 10.1200/JCO.22.00908.
    PubMed     Abstract available
    
    
    
18. BROOKS GA, Landrum MB, Kapadia NS, Liu PH, et al
    Impact of the Oncology Care Model on Use of Supportive Care Medications During Cancer Treatment.
    J Clin Oncol. 2022;40:1763-1771.
    PubMed     Abstract available
    
    
    
19. ZACHARAKIS N, Huq LM, Seitter SJ, Kim SP, et al
    Breast Cancers Are Immunogenic: Immunologic Analyses and a Phase II Pilot Clinical Trial Using Mutation-Reactive Autologous Lymphocytes.
    J Clin Oncol. 2022;40:1741-1754.
    PubMed     Abstract available
    
    
    May 2022
20. GIORDANO SH, Franzoi MAB, Temin S, Anders CK, et al
    Systemic Therapy for Advanced Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: ASCO Guideline Update.
    J Clin Oncol. 2022 May 31:JCO2200519. doi: 10.1200/JCO.22.00519.
    PubMed     Abstract available
    
    
    
21. RAMAKRISHNA N, Anders CK, Lin NU, Morikawa A, et al
    Management of Advanced Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer and Brain Metastases: ASCO Guideline Update.
    J Clin Oncol. 2022 May 31:JCO2200520. doi: 10.1200/JCO.22.00520.
    PubMed     Abstract available
    
    
    
22. BACHELOT T, Cottu P, Chabaud S, Dalenc F, et al
    Everolimus Added to Adjuvant Endocrine Therapy in Patients With High-Risk Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Primary Breast Cancer.
    J Clin Oncol. 2022 May 23:JCO2102179. doi: 10.1200/JCO.21.02179.
    PubMed     Abstract available
    
    
    
23. VAN GEEL JJL, Boers J, Elias SG, Glaudemans AWJM, et al
    Clinical Validity of 16alpha-[(18)F]Fluoro-17beta-Estradiol Positron Emission Tomography/Computed Tomography to Assess Estrogen Receptor Status in Newly Diagnosed Metastatic Breast Cancer.
    J Clin Oncol. 2022 May 18:JCO2200400. doi: 10.1200/JCO.22.00400.
    PubMed     Abstract available
    
    
    
24. BIDARD FC, Kaklamani VG, Neven P, Streich G, et al
    Elacestrant (oral selective estrogen receptor degrader) Versus Standard Endocrine Therapy for Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Results From the Randomized Phase III EMERALD Trial.
    J Clin Oncol. 2022 May 18:JCO2200338. doi: 10.1200/JCO.22.00338.
    PubMed     Abstract available
    
    
    
25. FALLET V, Sanchis-Borja M, Benusiglio PR, Cadranel J, et al
    Do Female BRCA2 Pathogenic Variant Carriers Have an Increased Risk of Lung Cancer?
    J Clin Oncol. 2022 May 12:JCO2200488. doi: 10.1200/JCO.22.00488.
    PubMed    
    
    
    
26. LIEBERMAN S, Goldvaser H, Levy-Lahad E
    Germline Pathogenic Variants in BRCA1 and BRCA2: Malignancies Beyond Female Breast and Ovarian Cancers.
    J Clin Oncol. 2022;40:1590-1594.
    PubMed    
    
    
    
27. DAMODARAN S, Zhao F, Deming DA, Mitchell EP, et al
    Phase II Study of Copanlisib in Patients With Tumors With PIK3CA Mutations: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol Z1F.
    J Clin Oncol. 2022;40:1552-1561.
    PubMed     Abstract available
    
    
    
28. LI S, Silvestri V, Leslie G, Rebbeck TR, et al
    Cancer Risks Associated With BRCA1 and BRCA2 Pathogenic Variants.
    J Clin Oncol. 2022;40:1529-1541.
    PubMed     Abstract available
    
    
    
29. SINGLETON AC, Raeside R, Hyun KK, Partridge SR, et al
    Electronic Health Interventions for Patients With Breast Cancer: Systematic Review and Meta-Analyses.
    J Clin Oncol. 2022 May 2:JCO2101171. doi: 10.1200/JCO.21.01171.
    PubMed     Abstract available
    
    
    April 2022
30. JIN Z, Zhang S, Zhang L, Chen Q, et al
    Artificial Intelligence Risk Model (Mirai) Delivers Robust Generalization and Outperforms Tyrer-Cuzick Guidelines in Breast Cancer Screening.
    J Clin Oncol. 2022 Apr 22:JCO2102908. doi: 10.1200/JCO.21.02908.
    PubMed    
    
    
    
31. ERIKSSON M, Conant EF, Kontos D, Hall P, et al
    Risk Assessment in Population-Based Breast Cancer Screening.
    J Clin Oncol. 2022 Apr 22:JCO2102827. doi: 10.1200/JCO.21.02827.
    PubMed    
    
    
    
32. DI MEGLIO A, Havas J, Gbenou AS, Martin E, et al
    Dynamics of Long-Term Patient-Reported Quality of Life and Health Behaviors After Adjuvant Breast Cancer Chemotherapy.
    J Clin Oncol. 2022 Apr 21:JCO2100277. doi: 10.1200/JCO.21.00277.
    PubMed     Abstract available
    
    
    
33. VLIEK SB, Noordhoek I, Meershoek-Klein Kranenbarg E, van Rossum AGJ, et al
    Daily Oral Ibandronate With Adjuvant Endocrine Therapy in Postmenopausal Women With Estrogen Receptor-Positive Breast Cancer (BOOG 2006-04): Randomized Phase III TEAM-IIB Trial.
    J Clin Oncol. 2022 Apr 20:JCO2100311. doi: 10.1200/JCO.21.00311.
    PubMed     Abstract available
    
    
    
34. LOPES CARDOZO JMN, Drukker CA, Rutgers EJT, Schmidt MK, et al
    Outcome of Patients With an Ultralow-Risk 70-Gene Signature in the MINDACT Trial.
    J Clin Oncol. 2022;40:1335-1345.
    PubMed     Abstract available
    
    
    
35. BEAVIS PA, Derrick EB, Loi S
    Challenges of Creating New Tumor-Infiltrating Lymphocyte for Combating Breast Cancer.
    J Clin Oncol. 2022 Apr 19:JCO2200284. doi: 10.1200/JCO.22.00284.
    PubMed    
    
    
    
36. BRAUER ER, Ganz PA
    Moving the Translational Needle in Breast Cancer Survivorship: Connecting Intervention Research to Clinical Practice.
    J Clin Oncol. 2022 Apr 19:JCO2200174. doi: 10.1200/JCO.22.00174.
    PubMed    
    
    
    
37. ANDRE F, Ismaila N, Allison KH, Barlow WE, et al
    Biomarkers for Adjuvant Endocrine and Chemotherapy in Early-Stage Breast Cancer: ASCO Guideline Update.
    J Clin Oncol. 2022 Apr 19:JCO2200069. doi: 10.1200/JCO.22.00069.
    PubMed     Abstract available
    
    
    
38. ASAZUMA K, Shimomura A, Shimizu C
    Antibody-Drug Conjugates as an Adjuvant Therapy for Human Epidermal Growth Factor Receptor 2-Positive Early Breast Cancer.
    J Clin Oncol. 2022 Apr 14:JCO2200135. doi: 10.1200/JCO.22.00135.
    PubMed    
    
    
    
39. KORDE LA, Somerfield MR, Hershman DL
    Use of Immune Checkpoint Inhibitor Pembrolizumab in the Treatment of High-Risk, Early-Stage Triple-Negative Breast Cancer: ASCO Guideline Rapid Recommendation Update.
    J Clin Oncol. 2022 Apr 13:JCO2200503. doi: 10.1200/JCO.22.00503.
    PubMed     Abstract available
    
    
    
40. DOWSETT M
    Testing Endocrine Response for Managing Primary Estrogen Receptor-Positive Breast Cancer.
    J Clin Oncol. 2022 Apr 12:JCO2200214. doi: 10.1200/JCO.22.00214.
    PubMed    
    
    
    
41. NITZ UA, Gluz O, Kummel S, Christgen M, et al
    Endocrine Therapy Response and 21-Gene Expression Assay for Therapy Guidance in HR+/HER2- Early Breast Cancer.
    J Clin Oncol. 2022 Apr 11:JCO2102759. doi: 10.1200/JCO.21.02759.
    PubMed     Abstract available
    
    
    
42. THORSEN LBJ, Overgaard J, Matthiessen LW, Berg M, et al
    Internal Mammary Node Irradiation in Patients With Node-Positive Early Breast Cancer: Fifteen-Year Results From the Danish Breast Cancer Group Internal Mammary Node Study.
    J Clin Oncol. 2022 Apr 8:JCO2200044. doi: 10.1200/JCO.22.00044.
    PubMed     Abstract available
    
    
    
43. GREENLEE H, Iribarren C, Rana JS, Cheng R, et al
    Risk of Cardiovascular Disease in Women With and Without Breast Cancer: The Pathways Heart Study.
    J Clin Oncol. 2022 Apr 6:JCO2101736. doi: 10.1200/JCO.21.01736.
    PubMed     Abstract available
    
    
    March 2022
44. NOZAWA K, Hattori M, Yoshimura A, Iwata H, et al
    Clinical Utility of Precision Medicine in Early Breast Cancer: What Is the Optimal Framework to Develop Precision Medicine?
    J Clin Oncol. 2022 Mar 31:JCO2200153. doi: 10.1200/JCO.22.00153.
    PubMed    
    
    
    
45. DE JONG VMT, Wang Y, Ter Hoeve ND, Opdam M, et al
    Prognostic Value of Stromal Tumor-Infiltrating Lymphocytes in Young, Node-Negative, Triple-Negative Breast Cancer Patients Who Did Not Receive (neo)Adjuvant Systemic Therapy.
    J Clin Oncol. 2022 Mar 30:JCO2101536. doi: 10.1200/JCO.21.01536.
    PubMed     Abstract available
    
    
    
46. QIN B, Kim K, Goldman N, Rundle AG, et al
    Multilevel Factors for Adiposity Change in a Population-Based Prospective Study of Black Breast Cancer Survivors.
    J Clin Oncol. 2022 Mar 25:JCO2102973. doi: 10.1200/JCO.21.02973.
    PubMed     Abstract available
    
    
    
47. VAZ-LUIS I, Di Meglio A, Havas J, El-Mouhebb M, et al
    Long-Term Longitudinal Patterns of Patient-Reported Fatigue After Breast Cancer: A Group-Based Trajectory Analysis.
    J Clin Oncol. 2022 Mar 15:JCO2101958. doi: 10.1200/JCO.21.01958.
    PubMed     Abstract available
    
    
    
48. SALERNO EA, Culakova E, Heckler CE, Janelsins MC, et al
    Reply to S. Ning et al.
    J Clin Oncol. 2022;40:916-918.
    PubMed    
    
    
    
49. DELAHUNTY R, Nguyen L, Craig S, Creighton B, et al
    TRACEBACK: Testing of Historical Tubo-Ovarian Cancer Patients for Hereditary Risk Genes as a Cancer Prevention Strategy in Family Members.
    J Clin Oncol. 2022 Mar 9:JCO2102108. doi: 10.1200/JCO.21.02108.
    PubMed     Abstract available
    
    
    
50. JATOI I
    Ductal Carcinoma In Situ and Breast Cancer Overdiagnosis.
    J Clin Oncol. 2022 Mar 4:JCO2102802. doi: 10.1200/JCO.21.02802.
    PubMed    
    
    
    
51. GRIMM LJ, Plichta JK, Hwang ES
    More Than Incremental: Harnessing Machine Learning to Predict Breast Cancer Risk.
    J Clin Oncol. 2022 Mar 4:JCO2102733. doi: 10.1200/JCO.21.02733.
    PubMed    
    
    
    
52. THOMAS A, Parsons HA, Smith KL
    Late Recurrence Following Early Breast Cancer.
    J Clin Oncol. 2022 Mar 3:JCO2200167. doi: 10.1200/JCO.22.00167.
    PubMed     Abstract available
    
    
    February 2022
53. JAHAN N, Cathcart-Rake EJ, Ruddy KJ
    Late Breast Cancer Survivorship: Side Effects and Care Recommendations.
    J Clin Oncol. 2022 Feb 28:JCO2200049. doi: 10.1200/JCO.22.00049.
    PubMed     Abstract available
    
    
    
54. HICKS D, O'Regan RM
    Improving Outcomes for High-Risk Hormone Receptor-Positive Breast Cancer With CDK Inhibition.
    J Clin Oncol. 2022 Feb 24:JCO2102850. doi: 10.1200/JCO.21.02850.
    PubMed     Abstract available
    
    
    
55. KEMP EB, Geerse OP, Knowles R, Woodman R, et al
    Mapping Systematic Reviews of Breast Cancer Survivorship Interventions: A Network Analysis.
    J Clin Oncol. 2022 Feb 16:JCO2102015. doi: 10.1200/JCO.21.02015.
    PubMed     Abstract available
    
    
    
56. PEDERSEN RN, Mellemkjaer L, Ejlertsen B, Norgaard M, et al
    Mortality After Late Breast Cancer Recurrence in Denmark.
    J Clin Oncol. 2022 Feb 16:JCO2102062. doi: 10.1200/JCO.21.02062.
    PubMed     Abstract available
    
    
    
57. ANG BH, Ho WK, Wijaya E, Kwan PY, et al
    Predicting the Likelihood of Carrying a BRCA1 or BRCA2 Mutation in Asian Patients With Breast Cancer.
    J Clin Oncol. 2022 Feb 10:JCO2101647. doi: 10.1200/JCO.21.01647.
    PubMed     Abstract available
    
    
    
58. ANDERSON DN, Port ER
    Surgery No More? Managing the Primary Tumor in Stage IV Breast Cancer.
    J Clin Oncol. 2022 Feb 4:JCO2102706. doi: 10.1200/JCO.21.02706.
    PubMed     Abstract available
    
    
    
59. PARAMANANDAM VS, Dylke E, Clark GM, Daptardar AA, et al
    Prophylactic Use of Compression Sleeves Reduces the Incidence of Arm Swelling in Women at High Risk of Breast Cancer-Related Lymphedema: A Randomized Controlled Trial.
    J Clin Oncol. 2022 Feb 2:JCO2102567. doi: 10.1200/JCO.21.02567.
    PubMed     Abstract available
    
    
    
60. PFOB A, Sidey-Gibbons C, Rauch G, Thomas B, et al
    Intelligent Vacuum-Assisted Biopsy to Identify Breast Cancer Patients With Pathologic Complete Response (ypT0 and ypN0) After Neoadjuvant Systemic Treatment for Omission of Breast and Axillary Surgery.
    J Clin Oncol. 2022 Feb 2:JCO2102439. doi: 10.1200/JCO.21.02439.
    PubMed     Abstract available
    
    
    
61. CARLOS RC, Obeng-Gyasi S, Cole SW, Zebrack BJ, et al
    Linking Structural Racism and Discrimination and Breast Cancer Outcomes: A Social Genomics Approach.
    J Clin Oncol. 2022 Feb 2:JCO2102004. doi: 10.1200/JCO.21.02004.
    PubMed    
    
    
    
62. BARTON DL, Pugh SL, Ganz PA, Plaxe SC, et al
    Randomized Controlled Phase II Evaluation of Two Dose Levels of Bupropion Versus Placebo for Sexual Desire in Female Cancer Survivors: NRG-CC004.
    J Clin Oncol. 2022;40:324-334.
    PubMed     Abstract available
    
    
    January 2022
63. ROYCE M, Osgood C, Mulkey F, Bloomquist E, et al
    FDA Approval Summary: Abemaciclib With Endocrine Therapy for High-Risk Early Breast Cancer.
    J Clin Oncol. 2022 Jan 27:JCO2102742. doi: 10.1200/JCO.21.02742.
    PubMed     Abstract available
    
    
    
64. RAFN BS, Christensen J, Larsen A, Bloomquist K, et al
    Prospective Surveillance for Breast Cancer-Related Arm Lymphedema: A Systematic Review and Meta-Analysis.
    J Clin Oncol. 2022 Jan 25:JCO2101681. doi: 10.1200/JCO.21.01681.
    PubMed     Abstract available
    
    
    
65. DI MEGLIO A, Havas J, Soldato D, Presti D, et al
    Development and Validation of a Predictive Model of Severe Fatigue After Breast Cancer Diagnosis: Toward a Personalized Framework in Survivorship Care.
    J Clin Oncol. 2022 Jan 21:JCO2101252. doi: 10.1200/JCO.21.01252.
    PubMed     Abstract available
    
    
    
66. NING S, Qiao K, Pan L
    Physical Activity Patterns and Cognitive Function in Patients With Breast Cancer.
    J Clin Oncol. 2022 Jan 21:JCO2102073. doi: 10.1200/JCO.21.02073.
    PubMed    
    
    
    
67. WRIGHT JL, Rahbar H, Obeng-Gyasi S, Carlos R, et al
    Overcoming Barriers in Ductal Carcinoma In Situ Management: From Overtreatment to Optimal Treatment.
    J Clin Oncol. 2022;40:225-230.
    PubMed    
    
    
    
68. SHEPHERD JH, Ballman K, Polley MC, Campbell JD, et al
    CALGB 40603 (Alliance): Long-Term Outcomes and Genomic Correlates of Response and Survival After Neoadjuvant Chemotherapy With or Without Carboplatin and Bevacizumab in Triple-Negative Breast Cancer.
    J Clin Oncol. 2022 Jan 19:JCO2101506. doi: 10.1200/JCO.21.01506.
    PubMed     Abstract available
    
    
    
69. EISEN A, Somerfield MR, Accordino MK, Blanchette PS, et al
    Use of Adjuvant Bisphosphonates and Other Bone-Modifying Agents in Breast Cancer: ASCO-OH (CCO) Guideline Update.
    J Clin Oncol. 2022 Jan 18:JCO2102647. doi: 10.1200/JCO.21.02647.
    PubMed     Abstract available
    
    
    
70. KWAN ML, Cheng RK, Iribarren C, Neugebauer R, et al
    Risk of Cardiometabolic Risk Factors in Women With and Without a History of Breast Cancer: The Pathways Heart Study.
    J Clin Oncol. 2022 Jan 13:JCO2101738. doi: 10.1200/JCO.21.01738.
    PubMed     Abstract available
    
    
    
71. JOENSUU H, Kellokumpu-Lehtinen PL, Huovinen R, Jukkola A, et al
    Adjuvant Capecitabine for Early Breast Cancer: 15-Year Overall Survival Results From a Randomized Trial.
    J Clin Oncol. 2022 Jan 12:JCO2102054. doi: 10.1200/JCO.21.02054.
    PubMed     Abstract available
    
    
    
72. KHAN SA, Zhao F, Goldstein LJ, Cella D, et al
    Early Local Therapy for the Primary Site in De Novo Stage IV Breast Cancer: Results of a Randomized Clinical Trial (EA2108).
    J Clin Oncol. 2022 Jan 7:JCO2102006. doi: 10.1200/JCO.21.02006.
    PubMed     Abstract available
    
    
    
73. MAYER EL, Fesl C, Hlauschek D, Garcia-Estevez L, et al
    Treatment Exposure and Discontinuation in the PALbociclib CoLlaborative Adjuvant Study of Palbociclib With Adjuvant Endocrine Therapy for Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Early Breast Cancer (PALLAS/AFT-05/AB
    J Clin Oncol. 2022 Jan 7:JCO2101918. doi: 10.1200/JCO.21.01918.
    PubMed     Abstract available
    
    
    December 2021
74. SCHNEIDER BP, Jiang G, Ballinger TJ, Shen F, et al
    BRE12-158: A Postneoadjuvant, Randomized Phase II Trial of Personalized Therapy Versus Treatment of Physician's Choice for Patients With Residual Triple-Negative Breast Cancer.
    J Clin Oncol. 2021 Dec 15:JCO2101657. doi: 10.1200/JCO.21.01657.
    PubMed     Abstract available
    
    
    
75. KROP IE, Im SA, Barrios C, Bonnefoi H, et al
    Trastuzumab Emtansine Plus Pertuzumab Versus Taxane Plus Trastuzumab Plus Pertuzumab After Anthracycline for High-Risk Human Epidermal Growth Factor Receptor 2-Positive Early Breast Cancer: The Phase III KAITLIN Study.
    J Clin Oncol. 2021 Dec 10:JCO2100896. doi: 10.1200/JCO.21.00896.
    PubMed     Abstract available
    
    
    
76. YADAV S, Hu C, Nathanson KL, Weitzel JN, et al
    Germline Pathogenic Variants in Cancer Predisposition Genes Among Women With Invasive Lobular Carcinoma of the Breast.
    J Clin Oncol. 2021;39:3918-3926.
    PubMed     Abstract available
    
    
    
77. GIORDANO SH, Freedman RA, Somerfield MR
    Abemaciclib With Endocrine Therapy in the Treatment of High-Risk Early Breast Cancer: ASCO Optimal Adjuvant Chemotherapy and Targeted Therapy Guideline Rapid Recommendation Update.
    J Clin Oncol. 2021 Dec 8:JCO2102677. doi: 10.1200/JCO.21.02677.
    PubMed     Abstract available
    
    
    
78. GNANT M, Dueck AC, Frantal S, Martin M, et al
    Adjuvant Palbociclib for Early Breast Cancer: The PALLAS Trial Results (ABCSG-42/AFT-05/BIG-14-03).
    J Clin Oncol. 2021 Dec 7:JCO2102554. doi: 10.1200/JCO.21.02554.
    PubMed     Abstract available
    
    
    November 2021
79. YALA A, Mikhael PG, Strand F, Lin G, et al
    Multi-Institutional Validation of a Mammography-Based Breast Cancer Risk Model.
    J Clin Oncol. 2021 Nov 12:JCO2101337. doi: 10.1200/JCO.21.01337.
    PubMed     Abstract available
    
    
    
80. WARREN LEG, Bellon JR
    Should Everyone With Ductal Carcinoma in Situ Receive Adjuvant Radiation?
    J Clin Oncol. 2021;39:3535-3540.
    PubMed     Abstract available
    
    
    
81. MCCORMICK B, Winter KA, Woodward W, Kuerer HM, et al
    Randomized Phase III Trial Evaluating Radiation Following Surgical Excision for Good-Risk Ductal Carcinoma In Situ: Long-Term Report From NRG Oncology/RTOG 9804.
    J Clin Oncol. 2021;39:3574-3582.
    PubMed     Abstract available
    
    
    October 2021
82. BORGES VF
    Options for Endocrine-Refractory, Hormone Receptor-Positive Breast Cancer: Which Target and When?
    J Clin Oncol. 2021 Oct 28:JCO2101910. doi: 10.1200/JCO.21.01910.
    PubMed     Abstract available
    
    
    
83. ADEMUYIWA FO, Salyer P, Tao Y, Luo J, et al
    Genetic Counseling and Testing in African American Patients With Breast Cancer: A Nationwide Survey of US Breast Oncologists.
    J Clin Oncol. 2021 Oct 18:JCO2101426. doi: 10.1200/JCO.21.01426.
    PubMed     Abstract available
    
    
    
84. PALMER JR, Zirpoli G, Bertrand KA, Battaglia T, et al
    A Validated Risk Prediction Model for Breast Cancer in US Black Women.
    J Clin Oncol. 2021 Oct 8:JCO2101236. doi: 10.1200/JCO.21.01236.
    PubMed     Abstract available
    
    
    September 2021
85. DE RUITER MB, Reneman L, Kieffer JM, Oldenburg HSA, et al
    Brain White Matter Microstructure as a Risk Factor for Cognitive Decline After Chemotherapy for Breast Cancer.
    J Clin Oncol. 2021 Sep 30:JCO2100627. doi: 10.1200/JCO.21.00627.
    PubMed     Abstract available
    
    
    
86. HENRY NL, Kim S, Hays RD, Diniz MA, et al
    Toxicity Index, Patient-Reported Outcomes, and Early Discontinuation of Endocrine Therapy for Breast Cancer Risk Reduction in NRG Oncology/NSABP B-35.
    J Clin Oncol. 2021 Sep 23:JCO2100910. doi: 10.1200/JCO.21.00910.
    PubMed     Abstract available
    
    
    
87. SHIMANUKI Y, Shimomura A, Yoshimura K, Terakado H, et al
    Are Platinum Drugs Ineffective for Triple-Negative Breast Cancer With Residual Invasive Disease After Neoadjuvant Chemotherapy?
    J Clin Oncol. 2021 Sep 23:JCO2101757. doi: 10.1200/JCO.21.01757.
    PubMed    
    
    
    
88. SHIMOI T, Noguchi E, Sudo K, Chua YJ, et al
    Critical Appraisal of Adjuvant Platinum-Based Chemotherapy for Basal Subtype Triple-Negative Breast Cancer With Residual Disease After Neoadjuvant Chemotherapy.
    J Clin Oncol. 2021 Sep 23:JCO2101537. doi: 10.1200/JCO.21.01537.
    PubMed    
    
    
    
89. TANAKA M, Shimomura A, Terakado H, Shimizu C, et al
    Adjuvant Treatment for Small-Size, Node-Negative, Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: Escalation or De-Escalation?
    J Clin Oncol. 2021 Sep 10:JCO2101716. doi: 10.1200/JCO.21.01716.
    PubMed    
    
    
    
90. JAYASEKERA J, Sparano JA, O'Neill S, Chandler Y, et al
    Development and Validation of a Simulation Model-Based Clinical Decision Tool: Identifying Patients Where 21-Gene Recurrence Score Testing May Change Decisions.
    J Clin Oncol. 2021;39:2893-2902.
    PubMed     Abstract available
    
    
    
91. TUNG N, Desai N
    Germline Genetic Testing for Women With Breast Cancer: Shifting the Paradigm From Whom to Test to Whom NOT to Test.
    J Clin Oncol. 2021 Sep 7:JCO2101761. doi: 10.1200/JCO.21.01761.
    PubMed    
    
    
    August 2021
92. TARANTINO P, Tolaney SM, Harbeck N, Cortes J, et al
    Anthracyclines for Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: Are We Ready to Let Them Go?
    J Clin Oncol. 2021 Aug 18:JCO2101059. doi: 10.1200/JCO.21.01059.
    PubMed    
    
    
    
93. BOWER JE, Partridge AH, Wolff AC, Thorner ED, et al
    Targeting Depressive Symptoms in Younger Breast Cancer Survivors: The Pathways to Wellness Randomized Controlled Trial of Mindfulness Meditation and Survivorship Education.
    J Clin Oncol. 2021 Aug 18:JCO2100279. doi: 10.1200/JCO.21.00279.
    PubMed     Abstract available
    
    
    
94. SALERNO EA, Culakova E, Kleckner AS, Heckler CE, et al
    Physical Activity Patterns and Relationships With Cognitive Function in Patients With Breast Cancer Before, During, and After Chemotherapy in a Prospective, Nationwide Study.
    J Clin Oncol. 2021 Aug 18:JCO2003514. doi: 10.1200/JCO.20.03514.
    PubMed     Abstract available
    
    
    
95. CONNOLLY RM, Zhao F, Miller KD, Lee MJ, et al
    E2112: Randomized Phase III Trial of Endocrine Therapy Plus Entinostat or Placebo in Hormone Receptor-Positive Advanced Breast Cancer. A Trial of the ECOG-ACRIN Cancer Research Group.
    J Clin Oncol. 2021 Aug 6:JCO2100944. doi: 10.1200/JCO.21.00944.
    PubMed     Abstract available
    
    
    
96. TUNG NM, Zakalik D, Somerfield MR
    Adjuvant PARP Inhibitors in Patients With High-Risk Early-Stage HER2-Negative Breast Cancer and Germline BRCA Mutations: ASCO Hereditary Breast Cancer Guideline Rapid Recommendation Update.
    J Clin Oncol. 2021 Aug 3:JCO2101532. doi: 10.1200/JCO.21.01532.
    PubMed     Abstract available
    
    
    July 2021
97. BURSTEIN HJ, Somerfield MR, Barton DL, Dorris A, et al
    Endocrine Treatment and Targeted Therapy for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer: ASCO Guideline Update.
    J Clin Oncol. 2021 Jul 29:JCO2101392. doi: 10.1200/JCO.21.01392.
    PubMed     Abstract available
    
    
    
98. MOY B, Rumble RB, Come SE, Davidson NE, et al
    Chemotherapy and Targeted Therapy for Patients With Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer That is Either Endocrine-Pretreated or Hormone Receptor-Negative: ASCO Guideline Update.
    J Clin Oncol. 2021 Jul 29:JCO2101374. doi: 10.1200/JCO.21.01374.
    PubMed     Abstract available
    
    
    
99. BODDICKER NJ, Hu C, Weitzel JN, Kraft P, et al
    Risk of Late-Onset Breast Cancer in Genetically Predisposed Women.
    J Clin Oncol. 2021 Jul 22:JCO2100531. doi: 10.1200/JCO.21.00531.
    PubMed     Abstract available
    
    
    
100. COBLEIGH MA, Anderson SJ, Siziopikou KP, Arthur DW, et al
     Comparison of Radiation With or Without Concurrent Trastuzumab for HER2-Positive Ductal Carcinoma In Situ Resected by Lumpectomy: A Phase III Clinical Trial.
     J Clin Oncol. 2021;39:2367-2374.
     PubMed     Abstract available
     
     
     
101. BRACKSTONE M, Baldassarre FG, Perera FE, Cil T, et al
     Management of the Axilla in Early-Stage Breast Cancer: Ontario Health (Cancer Care Ontario) and ASCO Guideline.
     J Clin Oncol. 2021 Jul 19:JCO2100934. doi: 10.1200/JCO.21.00934.
     PubMed     Abstract available
     
     
     
102. KAWAMURA Y, Shimomura A, Shimizu C
     Who Can Receive the Benefit of a Palbociclib Add-On in Patients With HR+HER2- Breast Cancer With Residual Disease After Neoadjuvant Chemotherapy?
     J Clin Oncol. 2021 Jul 6:JCO2101174. doi: 10.1200/JCO.21.01174.
     PubMed    
     
     
     
103. LAMBERTINI M, Blondeaux E, Bruzzone M, Perachino M, et al
     Pregnancy After Breast Cancer: A Systematic Review and Meta-Analysis.
     J Clin Oncol. 2021 Jul 1:JCO2100535. doi: 10.1200/JCO.21.00535.
     PubMed     Abstract available
     
     
     June 2021
104. TURAN V, Lambertini M, Lee DY, Wang E, et al
     Association of Germline BRCA Pathogenic Variants With Diminished Ovarian Reserve: A Meta-Analysis of Individual Patient-Level Data.
     J Clin Oncol. 2021;39:2016-2024.
     PubMed     Abstract available
     
     
     
105. BEYER KMM, Zhou Y, Laud PW, McGinley EL, et al
     Mortgage Lending Bias and Breast Cancer Survival Among Older Women in the United States.
     J Clin Oncol. 2021 Jun 15:JCO2100112. doi: 10.1200/JCO.21.00112.
     PubMed     Abstract available
     
     
     
106. SUEMASU T, Shimomura A, Shimizu C, Hashimoto K, et al
     Regarding the Appropriate Target and Duration of Chemoprevention in Breast Cancer.
     J Clin Oncol. 2021 Jun 14:JCO2101060. doi: 10.1200/JCO.21.01060.
     PubMed    
     
     
     
107. ERIKSSON M, Eklund M, Borgquist S, Hellgren R, et al
     Low-Dose Tamoxifen for Mammographic Density Reduction: A Randomized Controlled Trial.
     J Clin Oncol. 2021;39:1899-1908.
     PubMed     Abstract available
     
     
     
108. ROBSON M
     Management of Women With Breast Cancer and Pathogenic Variants in Genes Other Than BRCA1 or BRCA2.
     J Clin Oncol. 2021 Jun 9:JCO2100999. doi: 10.1200/JCO.21.00999.
     PubMed     Abstract available
     
     
     
109. GAO C, Polley EC, Hart SN, Huang H, et al
     Risk of Breast Cancer Among Carriers of Pathogenic Variants in Breast Cancer Predisposition Genes Varies by Polygenic Risk Score.
     J Clin Oncol. 2021 Jun 8:JCO2001992. doi: 10.1200/JCO.20.01992.
     PubMed     Abstract available
     
     
     
110. MAYER IA, Zhao F, Arteaga CL, Symmans WF, et al
     Randomized Phase III Postoperative Trial of Platinum-Based Chemotherapy Versus Capecitabine in Patients With Residual Triple-Negative Breast Cancer Following Neoadjuvant Chemotherapy: ECOG-ACRIN EA1131.
     J Clin Oncol. 2021 Jun 6:JCO2100976. doi: 10.1200/JCO.21.00976.
     PubMed     Abstract available
     
     
     
111. TOLANEY SM, Tayob N, Dang C, Yardley DA, et al
     Adjuvant Trastuzumab Emtansine Versus Paclitaxel in Combination With Trastuzumab for Stage I HER2-Positive Breast Cancer (ATEMPT): A Randomized Clinical Trial.
     J Clin Oncol. 2021 Jun 2:JCO2003398. doi: 10.1200/JCO.20.03398.
     PubMed     Abstract available
     
     
     May 2021
112. MOSKOWITZ CS, Ronckers CM, Chou JF, Smith SA, et al
     Development and Validation of a Breast Cancer Risk Prediction Model for Childhood Cancer Survivors Treated With Chest Radiation: A Report From the Childhood Cancer Survivor Study and the Dutch Hodgkin Late Effects and LATER Cohorts.
     J Clin Oncol. 2021 May 28:JCO2002244. doi: 10.1200/JCO.20.02244.
     PubMed     Abstract available
     
     
     
113. TOLANEY SM, Garrett-Mayer E, White J, Blinder VS, et al
     Updated Standardized Definitions for Efficacy End Points (STEEP) in Adjuvant Breast Cancer Clinical Trials: STEEP Version 2.0.
     J Clin Oncol. 2021 May 18:JCO2003613. doi: 10.1200/JCO.20.03613.
     PubMed     Abstract available
     
     
     
114. CONNOLLY RM, Leal JP, Solnes L, Huang CY, et al
     Updated Results of TBCRC026: Phase II Trial Correlating Standardized Uptake Value With Pathological Complete Response to Pertuzumab and Trastuzumab in Breast Cancer.
     J Clin Oncol. 2021 May 17:JCO2100280. doi: 10.1200/JCO.21.00280.
     PubMed     Abstract available
     
     
     
115. LIN NU, Pegram M, Sahebjam S, Ibrahim N, et al
     Pertuzumab Plus High-Dose Trastuzumab in Patients With Progressive Brain Metastases and HER2-Positive Metastatic Breast Cancer: Primary Analysis of a Phase II Study.
     J Clin Oncol. 2021 May 4:JCO2002822. doi: 10.1200/JCO.20.02822.
     PubMed     Abstract available
     
     
     
116. PRAT A, Chaudhury A, Solovieff N, Pare L, et al
     Correlative Biomarker Analysis of Intrinsic Subtypes and Efficacy Across the MONALEESA Phase III Studies.
     J Clin Oncol. 2021;39:1458-1467.
     PubMed     Abstract available
     
     
     April 2021
117. ALVA AS, Mangat PK, Garrett-Mayer E, Halabi S, et al
     Pembrolizumab in Patients With Metastatic Breast Cancer With High Tumor Mutational Burden: Results From the Targeted Agent and Profiling Utilization Registry (TAPUR) Study.
     J Clin Oncol. 2021 Apr 12:JCO2002923. doi: 10.1200/JCO.20.02923.
     PubMed     Abstract available
     
     
     
118. TAIRA N, Sawaki M, Uemura Y, Saito T, et al
     Health-Related Quality of Life With Trastuzumab Monotherapy Versus Trastuzumab Plus Standard Chemotherapy as Adjuvant Therapy in Older Patients With HER2-Positive Breast Cancer.
     J Clin Oncol. 2021 Apr 9:JCO2002751. doi: 10.1200/JCO.20.02751.
     PubMed     Abstract available
     
     
     
119. LOIBL S, Marme F, Martin M, Untch M, et al
     Palbociclib for Residual High-Risk Invasive HR-Positive and HER2-Negative Early Breast Cancer-The Penelope-B Trial.
     J Clin Oncol. 2021 Apr 1:JCO2003639. doi: 10.1200/JCO.20.03639.
     PubMed     Abstract available
     
     
     
120. ANDO K, Shimomura A, Yoshimura K, Kawamura Y, et al
     What Is the Optimal Model to Estimate the Benefits of Chemotherapy in Patients With Hormone Receptor-Positive, HER2-Negative, Node-Negative Breast Cancer?
     J Clin Oncol. 2021 Apr 1:JCO2100178. doi: 10.1200/JCO.21.00178.
     PubMed    
     
     
     March 2021
121. FASCHING PA, Yadav S, Hu C, Wunderle M, et al
     Mutations in BRCA1/2 and Other Panel Genes in Patients With Metastatic Breast Cancer -Association With Patient and Disease Characteristics and Effect on Prognosis.
     J Clin Oncol. 2021 Mar 29:JCO2001200. doi: 10.1200/JCO.20.01200.
     PubMed     Abstract available
     
     
     
122. CIRUELOS EM, Rugo HS, Mayer IA, Levy C, et al
     Patient-Reported Outcomes in Patients With PIK3CA-Mutated Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer From SOLAR-1.
     J Clin Oncol. 2021 Mar 29:JCO2001139. doi: 10.1200/JCO.20.01139.
     PubMed     Abstract available
     
     
     
123. MCDONNELL DP, Wardell SE, Chang CY, Norris JD, et al
     Next-Generation Endocrine Therapies for Breast Cancer.
     J Clin Oncol. 2021 Mar 11:JCO2003565. doi: 10.1200/JCO.20.03565.
     PubMed    
     
     
     February 2021
124. HASHIMOTO K, Shimomura A
     Regarding the Addition of CDK4/6 Inhibitor to Postoperative Endocrine Therapy in Patients With HR-Positive HER2-Negative High-Risk Breast Cancer.
     J Clin Oncol. 2021 Feb 25:JCO2003215. doi: 10.1200/JCO.20.03215.
     PubMed    
     
     
     
125. KURIAN AW, Ward KC, Abrahamse P, Bondarenko I, et al
     Time Trends in Receipt of Germline Genetic Testing and Results for Women Diagnosed With Breast Cancer or Ovarian Cancer, 2012-2019.
     J Clin Oncol. 2021 Feb 9:JCO2002785. doi: 10.1200/JCO.20.02785.
     PubMed     Abstract available
     
     
     
126. PICCART M, Procter M, Fumagalli D, de Azambuja E, et al
     Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer in the APHINITY Trial: 6 Years' Follow-Up.
     J Clin Oncol. 2021 Feb 4:JCO2001204. doi: 10.1200/JCO.20.01204.
     PubMed     Abstract available
     
     
     
127. SACKS GD, Morrow M
     Addressing the Dilemma of Contralateral Prophylactic Mastectomy With Behavioral Science.
     J Clin Oncol. 2021;39:269-272.
     PubMed    
     
     
     January 2021
128. BARDIA A, Kaklamani V, Wilks S, Weise A, et al
     Phase I Study of Elacestrant (RAD1901), a Novel Selective Estrogen Receptor Degrader, in ER-Positive, HER2-Negative Advanced Breast Cancer.
     J Clin Oncol. 2021 Jan 29:JCO2002272. doi: 10.1200/JCO.20.02272.
     PubMed     Abstract available
     
     
     
129. KORDE LA, Somerfield MR, Carey LA, Crews JR, et al
     Neoadjuvant Chemotherapy, Endocrine Therapy, and Targeted Therapy for Breast Cancer: ASCO Guideline.
     J Clin Oncol. 2021 Jan 28:JCO2003399. doi: 10.1200/JCO.20.03399.
     PubMed     Abstract available
     
     
     
130. ROSENBERGER LH, Thomas SM, Nimbkar SN, Hieken TJ, et al
     Contemporary Multi-Institutional Cohort of 550 Cases of Phyllodes Tumors (2007-2017) Demonstrates a Need for More Individualized Margin Guidelines.
     J Clin Oncol. 2021;39:178-189.
     PubMed     Abstract available
     
     
     
131. MAGNUSON A, Sedrak MS, Gross CP, Tew WP, et al
     Development and Validation of a Risk Tool for Predicting Severe Toxicity in Older Adults Receiving Chemotherapy for Early-Stage Breast Cancer.
     J Clin Oncol. 2021 Jan 14:JCO2002063. doi: 10.1200/JCO.20.02063.
     PubMed     Abstract available
     
     
     December 2020
132. MCNEIL CM
     Coronavirus Farewell.
     J Clin Oncol. 2020;38:4346-4348.
     PubMed    
     
     
     
133. AZIM HA JR, Ameye L, Paesmans M, Lambertini M, et al
     Reply to S. A. Narod et al.
     J Clin Oncol. 2020;38:4352-4354.
     PubMed    
     
     
     
134. MO DC, Luo PH, Huang JF, Huang SX, et al
     Neratinib Plus Capecibine in Patients With HER2-Positive Metastatic Breast Cancer.
     J Clin Oncol. 2020 Dec 17:JCO2002378. doi: 10.1200/JCO.20.02378.
     PubMed    
     
     
     
135. DEKKER TJA
     Neratinib in HER2-Positive Breast Cancer With Brain Metastases.
     J Clin Oncol. 2020 Dec 17:JCO2002385. doi: 10.1200/JCO.20.02385.
     PubMed    
     
     
     
136. DOWSETT M, Sestak I, Cuzick J
     Calibration of CTS5 in Women With Early Estrogen Receptor-Positive Breast Cancer.
     J Clin Oncol. 2020 Dec 16:JCO2002551. doi: 10.1200/JCO.20.02551.
     PubMed    
     
     
     
137. SPARANO JA, Crager MR, Tang G, Gray RJ, et al
     Development and Validation of a Tool Integrating the 21-Gene Recurrence Score and Clinical-Pathological Features to Individualize Prognosis and Prediction of Chemotherapy Benefit in Early Breast Cancer.
     J Clin Oncol. 2020 Dec 11:JCO2003007. doi: 10.1200/JCO.20.03007.
     PubMed     Abstract available
     
     
     
138. WRIGHT JL, Bellon JR
     Is the Time Right for Five-Fraction Partial Breast Irradiation?
     J Clin Oncol. 2020;38:4135-4137.
     PubMed    
     
     
     
139. BEKELMAN JE, Gupta A, Fishman E, Debono D, et al
     Association Between a National Insurer's Pay-for-Performance Program for Oncology and Changes in Prescribing of Evidence-Based Cancer Drugs and Spending.
     J Clin Oncol. 2020;38:4055-4063.
     PubMed     Abstract available
     
     
     
140. JAGSI R, Griffith KA, Vicini F, Boike T, et al
     Toward Improving Patients' Experiences of Acute Toxicity From Breast Radiotherapy: Insights From the Analysis of Patient-Reported Outcomes in a Large Multicenter Cohort.
     J Clin Oncol. 2020;38:4019-4029.
     PubMed     Abstract available
     
     
     November 2020
141. WEINSTEIN SP, Korhonen K, Cirelli C, Schnall MD, et al
     Abbreviated Breast Magnetic Resonance Imaging for Supplemental Screening of Women With Dense Breasts and Average Risk.
     J Clin Oncol. 2020;38:3874-3882.
     PubMed     Abstract available
     
     
     
142. RECHT A
     Hypofractionated Whole-Breast Irradiation: Case Closed?
     J Clin Oncol. 2020;38:3584-3586.
     PubMed    
     
     
     
143. WANG SL, Fang H, Hu C, Song YW, et al
     Hypofractionated Versus Conventional Fractionated Radiotherapy After Breast-Conserving Surgery in the Modern Treatment Era: A Multicenter, Randomized Controlled Trial From China.
     J Clin Oncol. 2020;38:3604-3614.
     PubMed     Abstract available
     
     
     
144. ANG E
     Four Women, One Evening.
     J Clin Oncol. 2020;38:3716-3718.
     PubMed    
     
     
     October 2020
145. NAROD SA, Giannakeas V
     In Response to "Pregnancy After Breast Cancer in Patients With Germline BRCA Mutations".
     J Clin Oncol. 2020 Oct 30:JCO2002253. doi: 10.1200/JCO.20.02253.
     PubMed    
     
     
     
146. TUNG NM, Robson ME, Ventz S, Santa-Maria CA, et al
     TBCRC 048: Phase II Study of Olaparib for Metastatic Breast Cancer and Mutations in Homologous Recombination-Related Genes.
     J Clin Oncol. 2020 Oct 29:JCO2002151. doi: 10.1200/JCO.20.02151.
     PubMed     Abstract available
     
     
     
147. BUUS R, Sestak I, Kronenwett R, Ferree S, et al
     Molecular Drivers of Oncotype DX, Prosigna, EndoPredict, and the Breast Cancer Index: A TransATAC Study.
     J Clin Oncol. 2020 Oct 27:JCO2000853. doi: 10.1200/JCO.20.00853.
     PubMed     Abstract available
     
     
     
148. FERNANDEZ-MARTINEZ A, Krop IE, Hillman DW, Polley MY, et al
     Survival, Pathologic Response, and Genomics in CALGB 40601 (Alliance), a Neoadjuvant Phase III Trial of Paclitaxel-Trastuzumab With or Without Lapatinib in HER2-Positive Breast Cancer.
     J Clin Oncol. 2020 Oct 23:JCO2001276. doi: 10.1200/JCO.20.01276.
     PubMed     Abstract available
     
     
     
149. DENDULURI N, Somerfield MR, Chavez-MacGregor M, Comander AH, et al
     Selection of Optimal Adjuvant Chemotherapy and Targeted Therapy for Early Breast Cancer: ASCO Guideline Update.
     J Clin Oncol. 2020 Oct 20:JCO2002510. doi: 10.1200/JCO.20.02510.
     PubMed     Abstract available
     
     
     
150. BUCHHOLZ TA, Ali S, Hunt KK
     Reply to A. Thomsen et al.
     J Clin Oncol. 2020;38:3577.
     PubMed    
     
     
     
151. ARAOYE EF, Stearns V, Aguh C
     Considerations for the Use of Scalp Cooling Devices in Black Patients.
     J Clin Oncol. 2020;38:3575-3576.
     PubMed    
     
     
     
152. DALLA VOLTA A, Mazziotti G, Maffezzoni F, Grisanti S, et al
     Bone Mineral Density and FRAX Score May Not Predict Fracture Risk in Patients With Cancer Undergoing Hormone Deprivation Therapies.
     J Clin Oncol. 2020;38:3363-3366.
     PubMed    
     
     
     
153. WHELAN T, Levine M, Sussman J
     Hypofractionated Breast Irradiation: What's Next?
     J Clin Oncol. 2020;38:3245-3247.
     PubMed    
     
     
     
154. MODI S, Park H, Murthy RK, Iwata H, et al
     Reply to T.J.A. Dekker.
     J Clin Oncol. 2020;38:3351-3352.
     PubMed    
     
     
     September 2020
155. MULDER RL, Hudson MM, Bhatia S, Landier W, et al
     Updated Breast Cancer Surveillance Recommendations for Female Survivors of Childhood, Adolescent, and Young Adult Cancer From the International Guideline Harmonization Group.
     J Clin Oncol. 2020 Sep 29:JCO2000562. doi: 10.1200/JCO.20.00562.
     PubMed     Abstract available
     
     
     
156. WOLFF AC
     CDK4/6 Inhibition in Early-Stage Breast Cancer: The New Standard?
     J Clin Oncol. 2020 Sep 20:JCO2002688. doi: 10.1200/JCO.20.02688.
     PubMed    
     
     
     
157. JOHNSTON SRD, Harbeck N, Hegg R, Toi M, et al
     Abemaciclib Combined With Endocrine Therapy for the Adjuvant Treatment of HR+, HER2-, Node-Positive, High-Risk, Early Breast Cancer (monarchE).
     J Clin Oncol. 2020 Sep 20:JCO2002514. doi: 10.1200/JCO.20.02514.
     PubMed     Abstract available
     
     
     
158. LIGIBEL JA
     Reply to R.T. Chlebowski et al.
     J Clin Oncol. 2020;38:3072-3073.
     PubMed    
     
     
     August 2020
159. JAFFE ES, Feldman AL, Gaulard P, Miranda RN, et al
     Reply to M. Romero et al.
     J Clin Oncol. 2020;38:2819-2820.
     PubMed    
     
     
     
160. TUNG N, Hacker MR, Garber JE
     Reply to S. Takamizawa et al.
     J Clin Oncol. 2020;38:2700-2701.
     PubMed    
     
     
     
161. TING FIL
     The Road Less Traveled: Serving the Underserved.
     J Clin Oncol. 2020;38:2597-2598.
     PubMed    
     
     
     July 2020
162. SHUMWAY DA, Momoh AO, Sabel MS, Jagsi R, et al
     Integration of Breast Reconstruction and Postmastectomy Radiotherapy.
     J Clin Oncol. 2020;38:2329-2340.
     PubMed    
     
     
     
163. MORROW M, Khan AJ
     Locoregional Management After Neoadjuvant Chemotherapy.
     J Clin Oncol. 2020;38:2281-2289.
     PubMed    
     
     
     
164. HWANG ES, Solin L
     De-Escalation of Locoregional Therapy in Low-Risk Disease for DCIS and Early-Stage Invasive Cancer.
     J Clin Oncol. 2020;38:2230-2239.
     PubMed    
     
     
     
165. WHITE J, Thompson A, Whelan T
     Accelerated Partial Breast Irradiation and Intraoperative Partial Breast Irradiation: Reducing the Burden of Effective Breast Conservation.
     J Clin Oncol. 2020;38:2254-2262.
     PubMed    
     
     
     
166. MAMOUNAS EP, Mitchell MP, Woodward WA
     Molecular Predictive and Prognostic Markers in Locoregional Management.
     J Clin Oncol. 2020;38:2310-2320.
     PubMed    
     
     
     
167. CATHCART-RAKE EJ, Ruddy KJ
     Smart Technology and Endocrine Therapy Adherence.
     J Clin Oncol. 2020;38:2117-2118.
     PubMed    
     
     
     June 2020
168. LLUCH A, Barrios CH, Torrecillas L, Martin M, et al
     Reply to Y. Usui et al.
     J Clin Oncol. 2020;38:2113-2114.
     PubMed    
     
     
     
169. AMBROSONE CB, Hutson AD
     Reply to E. Javor et al.
     J Clin Oncol. 2020;38:2111.
     PubMed    
     
     
     
170. ROMERO M, Melo A, Bedoya N, de la Hoz J, et al
     Should Flow Cytometry Be Considered a First Line of Study in the Diagnosis of Breast Implant-Associated Anaplastic Large-Cell Lymphoma?
     J Clin Oncol. 2020 Jun 17:JCO2000712. doi: 10.1200/JCO.20.00712.
     PubMed    
     
     
     April 2020
171. LAZZERONI M, DeCensi A
     De-Escalating Treatment of Low-Risk Breast Ductal Carcinoma In Situ.
     J Clin Oncol. 2020;38:1252-1254.
     PubMed    
     
     
     
172. HWANG ES, Hyslop T, Hendrix LH, Duong S, et al
     Phase II Single-Arm Study of Preoperative Letrozole for Estrogen Receptor-Positive Postmenopausal Ductal Carcinoma In Situ: CALGB 40903 (Alliance).
     J Clin Oncol. 2020;38:1284-1292.
     PubMed     Abstract available
     
     
     
173. PAGANI O, Francis PA, Fleming GF, Walley BA, et al
     Absolute Improvements in Freedom From Distant Recurrence to Tailor Adjuvant Endocrine Therapies for Premenopausal Women: Results From TEXT and SOFT.
     J Clin Oncol. 2020;38:1293-1303.
     PubMed     Abstract available
     
     
     
174. STEBBING J, Mainwaring PN, Curigliano G, Pegram M, et al
     Understanding the Role of Comparative Clinical Studies in the Development of Oncology Biosimilars.
     J Clin Oncol. 2020;38:1070-1080.
     PubMed     Abstract available
     
     
     
175. CHIEN AJ, Tripathy D, Albain KS, Symmans WF, et al
     MK-2206 and Standard Neoadjuvant Chemotherapy Improves Response in Patients With Human Epidermal Growth Factor Receptor 2-Positive and/or Hormone Receptor-Negative Breast Cancers in the I-SPY 2 Trial.
     J Clin Oncol. 2020;38:1059-1069.
     PubMed     Abstract available
     
     
     March 2020
176. BEEBE-DIMMER JL, Kapron AL, Fraser AM, Smith KR, et al
     Risk of Prostate Cancer Associated With Familial and Hereditary Cancer Syndromes.
     J Clin Oncol. 2020 Mar 24:JCO1902808. doi: 10.1200/JCO.19.02808.
     PubMed     Abstract available
     
     
     
177. YANG X, Leslie G, Doroszuk A, Schneider S, et al
     Cancer Risks Associated With Germline PALB2 Pathogenic Variants: An International Study of 524 Families.
     J Clin Oncol. 2020;38:674-685.
     PubMed     Abstract available
     
     
     February 2020
178. JAFFE ES, Ashar BS, Clemens MW, Feldman AL, et al
     Best Practices Guideline for the Pathologic Diagnosis of Breast Implant-Associated Anaplastic Large-Cell Lymphoma.
     J Clin Oncol. 2020 Feb 11:JCO1902778. doi: 10.1200/JCO.19.02778.
     PubMed     Abstract available
     
     

Thank you for your interest in scientific medicine.

AMEDEO Breast Cancer is free of charge. This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim. Design: